High-Dose Ara-C with R-CHOP and Autologous Stem Cell Transplant (ASCT) in Mantle-Cell Lymphoma


High-Dose Ara-C with R-CHOP and Autologous Stem Cell Transplant (ASCT) in Mantle-Cell Lymphoma
Slides from a presentation at ASH 2010 and transcribed comments from a recent interview with Lauren C Pinter-Brown, MD (1/7/11)

Hermine O et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high-dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL Younger trial of the European Mantle Cell Lymphoma Network (MCL net). Proc ASH 2010;Abstract 110.

Dr Pinter-Brown is Director of the UCLA Lymphoma Program and Clinical Professor of Medicine at Geffen School of Medicine at UCLA in Los Angeles, California.